The Synergistic, amplifying use of Micronized Purified Flavanoid Fraction, proprietary ceramide emulsion, and dermal microdeformation fuzzy wale compression under inelastic compression for the management of Venous Leg Ulcers

Matthew M. Melin, MD, FACS, RPVI, FACWSS; Jennifer Reinders, WOCN; Angie Wubben, WOCN; Katie Cecconi, PA
Wound Healing Institute, M Health Fairview, Edina, MN

SYNOPSIS

Venous Leg Ulcers (VLUs), based upon revision of the Starling principle in 2010 (1), are now recognized to be associated with significant dermal and deep-lymphatic dysfunction in addition to Chronic Venous Insufficiency (CVI), also known as phlebolymphedema. Dermatitis is a near consistent, aggravating component of VLUs and contribute to wound non-closure and early recidivism. The standard of care VLU treatment has typically focused on venous procedures/ablation in an attempt to eliminate the superficial venous hypertension component of CVI and graded compression stocking utilizing with little attention to the dermatisis component (2). Our Wound Clinic practice has begun to actively manage the dermatitis component of VLU's through consistent use of: 1) oral Micronized Purified Flavanoid Fraction (diosmiplex 630mg) (3.4), 2) proprietary emulsion composed of a 3:1:1 ratio of Ceramide: Conjugated linoleic acid: cholesterol (5.6), and 3) fuzzy wale compression garment (7,8) applied under inelastic compression to achieve minimum 20-30mmHg gradient compression.

RESULTS

Case #1

67 year old male, CVI, phlebolymphedema, complicated by work related chemical burn. Non diabetic, no tobacco use. ABIs normal, no PAD.

DAY 1
- Surgical Debridement day 2 and 67 (application cadaver skin)
- Note longitudinal dermal microdeformation from fuzzy wale
- Day 104, closed VLU, pain markedly improved, Dermatitis improved. Continued daily ceramide, MPFF (diosmiplex 630mg), graded compression

Case #2

83 year old female, CVI, phlebolymphedema, obesity, adult onset diabetes, no PAD. No h/o DVT, PE.

DAY 1
- Chronic spinal stenosis, back pain, difficulty using leg.
- Underwent radiofrequency ablation of incompetent R GSV 2 months prior to Wound Clinic consult, no improvement of wound size or pain. Post procedure use of standard 30-40mmHg graded static compression stocking, foam dressing to wound.
- Multiple courses of antibiotic therapy.

DAY 71
- Telehealth visit
- Wound closed, improved dermatitis

Case #3

45 year old male, obesity, AODM, prior left GSV striping, no PAD, no tobacco use. Multiple episodes of cellulitis, chronic interstitial edema, lymphoedema.

DAY 1
- Day 1 initiation MPFF (diosmiplex 630mg), proprietary 3:1:1 ceramide dominant emulsion, fuzzy wale dermal compression under inelastic compression (applied by husband).

METHODS

A case series of three patients with CVI, Phlebolymphedema, VLU and dermatitis

- Debridement, biopsies as indicated, Ankle Brachial Indices (ABI) and venous insufficiency ultrasounds were performed
- Patients were initiated on oral MPFF (diosmiplex 630mg (Vascuella)), proprietary 3:1:1 ceramide dominant emulsion
- (EpCeram), fuzzy wale dermal microdeformation compression under inelastic compression
- VLU specific dressing including HCCL washes and an antibacterial foam
- Adjunctive micronutrient therapy consisting of Vitamin D, C, B12 and folate are advised
- MITFHR status is evaluated, B12 and Folate are utilized if hetero- or homozgyous to improve endothelial functionality

OBJECTIVE

Assess use of simultaneous treatment methods for accelerated wound healing and dermatitis improvement

CONCLUSIONS

The dermal lymphatic component of VLU's and CVI remains a significantly underrecognized, under-appreciated and undermanaged component of treatment, resulting in slow wound closure times and unacceptable high recidivism rates. The synergistic, amplifying, consistent application of the 4 components of oral MPFF (diosmiplex 630mg), proprietary 3:1:1 ceramide dominant emulsion, fuzzy wale dermal microdeformation under inelastic compression resulted in accelerated wound closure outcomes for the 3 patient series described. The impact of oral MPFF (diosmiplex 630mg) of increased lymphatic and venous tone with decreased ICAM and VCAM, combined with direct dermal lymphatic stimulation, potentially resulting in increased lymphangion contractility, significantly reduces interstitial edema. A larger, randomized controlled clinical trial is indicated.

REFERENCES